Reuters logo
BRIEF-Incyte and MacroGenics announce global collaboration and licensing agreement
2017年10月25日 / 上午11点01分 / 1 个月前

BRIEF-Incyte and MacroGenics announce global collaboration and licensing agreement

Oct 25 (Reuters) - Incyte Corp

* Incyte and MacroGenics announce global collaboration and licensing agreement for Anti-PD-1 Monoclonal Antibody MGA012

* MacroGenics inc - ‍Incyte gains exclusive, worldwide development and commercialization rights to MGA012 in all indications​

* MacroGenics Inc - ‍upon closing, Incyte will pay MacroGenics an upfront payment of $150 million​

* MacroGenics - ‍co is eligible to receive up to $420 million in potential development, regulatory milestones, up to $330 million in potential commercial milestones​

* MacroGenics Inc - ‍MacroGenics retains right to manufacture a portion of both companies’ global clinical and commercial supply needs of MGA012​

* MacroGenics Inc - ‍MacroGenics intends to utilize its commercial-scale GMP facility, which is expected to be fully operational in 2018​

* MacroGenics - ‍if MGA012 approved & commercialized, co will be eligible to get royalties, tiered from 15 percent to 24 percent, on future sales by Incyte​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below